Rise in prevalence of rheumatoid arthritis, increase in elderly population, and surge in incidence of obesity worldwide fuel the growth of the global anti-rheumatics market. On the other hand, side effects related to the medication and higher cost of biologics & biosimilars curtail down the growth to certain extent. However, R&D activities in the field of biosimilars and novel biologics are expected to pave the way for multiple opportunities in the industry.
According to the report published by Allied Market Research, the global anti-rheumatics industry accounted for $57.22 billion in 2018, and is estimated to reach $71.93 billion by 2026, growing at a CAGR of 2.9% from 2019 to 2026. The report provides a detailed analysis of changing market dynamics, top segments, value chain, key investment pockets, regional scenario, and competitive landscape.
Request Report Sample at: https://www.alliedmarketresearch.com/request-sample/6289
Onkar Sumant, a Manager, Healthcare at Allied Market Research, stated, The demand for anti-rheumatics is on the rise, owing to surge in incidence of rheumatoid arthritis worldwide. Furthermore, surge in geriatric population across the globe is another major factor that fuels the growth of the market.
In 2018, North America accounted for the major share of anti-rheumatics market size and is expected to remain dominant, owing to easy availability of the anti-rheumatics in this region. Moreover, surge in geriatric population in the region is another major factor that fuels the growth of anti-rheumatic market. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period, owing to surge in awareness related to the use of anti-rheumatics.
The prescription-based drugs segment to maintain its dominance by 2026
Based on type, the prescription-based drugs segment accounted for the highest share in the global anti-rheumatics market in 2018, contributing for more than three-fourths of the total share, and is estimated to maintain its dominance in terms of revenue throughout the forecast period. This is due to increase in the number of specialized hospitals across the world that provide treatment from specialized medical professionals. However, the over-the-counter drugs segment is estimated to register the highest CAGR of 3.3% from 2019 to 2026, owing to surge in awareness related to treatment options and ease in availability.
For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/6289
Leading market players
- Pfizer, Inc.
- Johnson & Johnsons
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Celegene Corporations
- MedImmune, LLC
- Takeda Pharmaceutical Company Ltd.
- Biogen Inc.
- Celltrion Inc.
- Amgen Inc.
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free: 1-800-792-5285 |UK: +44-845-528-1300 | Hong Kong: +852-301-84916 | India (Pune): +91-20-66346060 | Fax: +1-855-550-5975 Email” email@example.com
Follow us on LinkedIn, Facebook, Twitter, Pinterest, YouTube & Instagram